tbuckley/cabot-search huggingface dataset:
Abstract 12777: High Sensitivity Troponin T is Associated With Increased Heart Failure Risk in Metabolic Syndrome in the Atherosclerosis Risk in Communities (ARIC) Study
Authors: Yashashwi Pokharel, Wensheng Sun, Dennis Villarael, Elizabeth Selvin, Salim Virani, Chiadi Ndumele, Ron Hoogeveen, Josef Coresh, Eric Boerwinkle, Kenneth Butler, Scott Solomon, James Pankow, Biykem Bozkurt, Christie Ballantyne, Vijay Nambi
Journal: Circulation (2014)

Background: Metabolic syndrome (MS) is associated with higher CVD risk. High sensitivity troponin T (hsTnT) is a marker of myocardial injury and an emerging marker for heart failure (HF) risk prediction. We examined whether hsTnT is associated with increased HF risk in people with similar number of MS components present at baseline in 10316 ARIC participants without prevalent HF. Methods: We used Wald Chi-square test to assess the interaction between MS and hsTnT and Cox model for the association of incident HF hospitalization by hsTnT categories across groups created by the number of MS components after adjusting for risk factors and NT-proBNP (Table). Results: The mean age of the study population was 63 (SD, 6) years (56% women). Mean hsTnT levels were higher with increasing MS components (Table). There were 1353 HF hospitalizations over a median of 14 years. The interaction of MS with hsTnT for HF was borderline significant (p-interaction 0.059). Compared to individuals without MS and hsTnT&lt;5 ng/L the HRs (95%CIs) were 1.7 (1.4-2.1) in those without MS and hsTnT≥5 ng/L; 1.7 (1.3-2.1) in MS and hsTnT&lt;5 ng/L; and 3.6 (3.0-4.4) in MS and hsTnT≥5 ng/L. In groups with 1-5 MS components present, increasing hsTnT was significantly associated with higher hazards for HF in each group with the highest HR in those with all 5 MS components (Table). Conclusion: Presence of higher MS risk components was associated with increasing subclinical myocardial injury as assessed by higher hsTnT. The hazards for HF were numerically similar in individuals without MS but detectable hsTnT (&gt;5 ng/L) as to those with MS but undetectable hsTnT. In people with similar number of MS components higher hsTnT levels were associated with increased HF hazards suggesting that in MS hsTnT could be a useful marker for identifying those at higher risk for incident HF.
Lipoylated and unlipoylated domains of human PDC-E2 as autoantigens in primary biliary cirrhosis: Significance of lipoate attachment
Authors: J Quinn
Journal: Hepatology (1993)

Approximately 95% of patients with primary biliary cirrhosis have antimitochondrial antibodies against the E2 component of the pyruvate dehydrogenase complex (E2p). Immunodominant sites on E2p have been localized to the inner lipoyl domain, which serves as a covalent attachment site for the essential cofactor, lipoic acid. However, it is not clear whether the presence of lipoic acid is necessary for autoimmune recognition of human E2p. To facilitate further studies on the inner lipoyl domain and to assess the importance of lipoic acid in antibody binding, we used the previously cloned human E2p cDNA in the construction and high-level expression in Escherichia coli of a subgene encoding the domain. Purification and analysis of the gene product revealed that both lipoylated and unlipoylated forms of the intact domain are generated. Immunoblotting, enzyme-linked immunosorbent assay inhibition experiments and antibody affinity measurements using isolated lipoylated and unlipoylated domains demonstrated that the presence of the lipoyl residue is crucial for effective recognition by primary biliary cirrhosis patients' autoantibodies, which have a higher relative affinity for the lipoylated form. Contrary to some previous suggestions, these results indicate that antibodies in primary biliary cirrhosis patients' sera bind most effectively to a unique peptide-cofactor conformation in the lipoyl domain of the human E2p polypeptide. Moreover, the availability of large amounts of human lipoyl domain will permit further studies into the role of the antigen (if any) in disease pathogenesis. (HEPATOLOGY 1993;18:1384–1391.)
Images in Clinical Medicine
Authors: Jerome P. Kassirer
Journal: New England Journal of Medicine (1992)

Visual images are a rich source of the information we use in clinical medicine, yet we expend little effort to enhance our perception and recognition of these images. A new feature introduced in this issue of the Journal, Images in Clinical Medicine, will present a broad representation of useful and clinically important visual images. We believe that exposure to these photographs will help sharpen the reader's ability to identify common forms. As doctors we encounter an enormous variety of images from day to day, including skin lesions, funduscopic views, blood smears, bone marrow smears, urine sediments, microbiologic specimens, joint . . .
The legal systems in the United States
Authors: A. R. Holder
Journal: JAMA (1974)

THE purpose of any legal system is to provide a framework within which members of society may co-exist as peaceably as possible. Further, law is used to enforce the minimum value system that the government considers necessary for group order, and to establish the freedoms, if any, that the political philosophy prevailing in the nation guarantees to the inhabitants. While the world's legal systems are widely different results of divergent philosophies, the purpose of the legal systems is usually quite similar. Legal systems tend to adopt a rather negative view of human behavior. They restrict undesirable, but do not usually reward desirable and ethical behavior. If a citizen of the United States makes fraudulent statements on his income tax returns, he may well go to prison. If a surgeon leaves a hemostat in a patient's abdomen and the patient chooses to sue, the surgeon will probably be required to pay
Abstract 7: Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B
Authors: Xiang Li, Haitao Li, Shengqing Li, Feng Zhu, Dong Joon Kim, Hua Xie, Yan Li, Janos Nadas, Naomi Oi, Tatyana Zykova, Dong Hoon Yu, Mee-Hyun Lee, Myoung Ok Kim, Lei Wang, Wei Ya Ma, Ronald A. Lubet, Ann M. Bode, Ziming Dong, Zigang Dong
Journal: Cancer Research (2017)

Abstract Ceftriaxone, an FDA-approved third-generation cephalosporin antibiotic, has antimicrobial activity against both gram-positive and gram-negative organisms. Generally, ceftriaxone is used for a variety of infections such as community-acquired pneumonia, meningitis and gonorrhea. Its primary molecular targets are the penicillin-binding proteins. However, other activities of ceftriaxone remain unknown. Herein, we report for the first time that ceftriaxone has antitumor activity in vitro and in vivo. Kinase profiling results predicted that Aurora B might be a potential ‘off’ target of ceftriaxone. Pull-down assay data confirmed that ceftriaxone could bind with Aurora B in vitro and in A549 cells. Furthermore, ceftriaxone (500 µM) suppressed anchorage-independent cell growth by targeting Aurora B in A549, H520 and H1650 lung cancer cells. Importantly, in vivo xenograft animal model results showed that ceftriaxone effectively suppressed A549 and H520 lung tumor growth by inhibiting Aurora B. These data suggest the anticancer efficacy of ceftriaxone for the treatment of lung cancers through its inhibition of Aurora B. Citation Format: Xiang Li, Haitao Li, Shengqing Li, Feng Zhu, Dong Joon Kim, Hua Xie, Yan Li, Janos Nadas, Naomi Oi, Tatyana Zykova, Dong Hoon Yu, Mee-Hyun Lee, Myoung Ok Kim, Lei Wang, Wei Ya Ma, Ronald A. Lubet, Ann M. Bode, Ziming Dong, Zigang Dong. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 7. doi:10.1158/1538-7445.AM2017-7
Outbreaks of Cyclospora cayetanensis Infection—United States, 1996
Journal: JAMA (1996)

Cyclospora cayetanensis (previously termed cyanobacterium-like body) is a recently characterized coccidian parasite; the first known cases of infection in humans were diagnosed in 1977. Before 1996, only three outbreaks of Cyclospora infection had been reported in the United States. This report describes the preliminary findings of an ongoing outbreak investigation by the South Carolina Department of Health and Environmental Control (SCDHEC) and summarizes the findings from investigations in other states.
Ueber das Problem der bösartigen Geschwülste. Eine experimentelle und theoretische Untersuchung.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pulmonary embolism
Authors: G. Meyer, P.-M. Roy, S. Gilberg, A. Perrier
Journal: BMJ (2010)

Complete occlusion of a peripheral pulmonary artery usually results in a pulmonary infarction with pleuritic chest pain and haemoptysis. When the blood clot is lodged in more proximal pulmonary arteries and is not occlusive, pulmonary infarction does not occur and pulmonary embolism might present as isolated dyspnoea. Massive pulmonary embolism is caused by large bilateral proximal clots resulting in haemodynamic collapse.1 #### Case scenario A non-smoking, previously well woman in her 70s complained of recent onset of dyspnoea. She had no cardiovascular or thromboembolic risk factors and clinical examination was normal apart from a heart rate of 96 beats per minute. With no clear explanation for the symptoms, her general practitioner applied a decision rule (table⇓) to evaluate the clinical probability of pulmonary embolism. The result was intermediate, prompting him to request a D-dimer level, which was raised. He referred the patient to hospital, where pulmonary embolism was confirmed on computed tomography. View this table: #### How common is it?
Abstract 5765: 3T MRI Molecular Imaging of Benfluorex Treatment of Metabolic Syndrome with α <sub>v</sub> β <sub>3</sub> -Integrin Targeted Nanoparticles
Authors: Kejia Cai, Wenjing Huang, Todd A Williams, Huiying Zhang, Shelton D Caruthers, Gregory M Lanza, Samuel A Wickline, Patrick M Winter
Journal: Circulation (2008)

1.5T MRI with α v β 3 -integrin targeted gadolinium nanoparticle contrast agents (NP) can detect stage I atherosclerosis in experimental animals by localizing specifically to inflammatory plaque components within minutes after injection. We hypothesized that NP could serve as an early surrogate biomarker of therapeutic efficacy for benfluorex treatment of metabolic syndrome in diabetic JCR-LA:cp rats on a 3T clinical scanner. Six week old JCR-LA:cp rats (n=6) received benfluorex in their feed (0.069% wt/wt) for 16 weeks, while control animals (n=5) received regular diet. The abdominal aorta was imaged (T1w spin echo) in 4 cross-sections at baseline and 2-hour post-injection (IV, 1.0 ml/kg NP) every 4 wks with a 3.0 T whole-body clinical MRI scanner, and total aortic wall signal was computed across all sections. Treatment of diabetic JCR-LA:cp rats with benfluorex reduced food consumption and body weight (16.0%; p&lt;0.05); and fasting plasma insulin, leptin and triglyceride were decreased by 52.6%, 18.2% and 36.2% in treated animals. Aortic wall signal for untreated animals rose progressively, whereas signal in treated animals progressively decreased, indicative of attenuation of angiogenesis and vascular inflammation (Figure , *p&lt;0.05). These observations represent the first report of the use of molecular imaging with an MRI surrogate biomarker at clinical field strength for quantifying therapeutic efficacy in a model of metabolic syndrome. This research has received full or partial funding support from the American Heart Association, AHA Midwest Affiliate (Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, South Dakota &amp; Wisconsin).
Further Therapeutic Tests with an Anti-Leprosy Serum (in Netherlands East Indies and Other Countries)
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dermatofibrosarcoma Protuberans Clinical Practice Guidelines in Oncology
Journal: Journal of the National Comprehensive Cancer Network (2004)

Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low-grade sarcoma of fibroblast origin with an incidence rate of 0.8 cases per million persons per year. It rarely metastasizes. However, initial misdiagnosis, prolonged time to correct diagnosis, and large tumor size at the time of diagnosis are common. NCCN's Non-Melanoma Skin Cancer panel has developed a guideline outlining treatment of DFSP to supplement the squamous cell and basal cell skin cancers guidelines. The NCCN Sarcoma Panel also provided expert input in the development of this DFSP guideline.For the most recent version of the guidelines, please visit NCCN.org
Clinical Hematology
Authors: William R. Best
Journal: JAMA (1968)

<h3>Laboratory Medicine: Hematology,</h3> by John B. Miale, ed 3; 1,257 pp, 555 illus, 25 plates, $21, St. Louis: C. V. Mosby Co., 1967. These are the two foremost hematologic texts of today, and it is a pleasure to be able to review the latest editions side by side. The current revisions are in keeping with evolving information in this discipline and consistent with previously established standards of scholarship. In common, these two books present a comprehensive view of blood diseases. They are well organized, indexed, and documented. A sizeable bibliography containing both current and older key articles is included in each. Updated views are given of the hemoglobinopathies, paraproteinemias, and of the blood groups. Improved and expanded electron photomicrographs are seen in both, but particularly in Miale. A number of new diagrams and pictures have been added; some old ones have been revised. If one were permitted to take only
TOC
Authors: Andrzej Mazur, Christine Feillet-Coudray, Dominique Bayle, Elyett Gueux, Marc Ruivard, Charles Coudray, Yves Rayssiguier, Chung-Lin Chen, Zhewei Fei, Edward Carter, Xiao-Ming Lu, Rey-Heng Hu, Vernon Young, Ronald Tompkins, Yong-Ming Yu, Thomas Wilson, Thomas Foxall, Robert Nicolosi, Ataru Taniguchi, Mitsuo Fukushima, Yutaka Seino, Masahiko Sakai, Satoru Yoshii, Shoichiro Nagasaka, Ichizoh Yamauchi, Takahide Okumura, Kazuko Nin, Kunpei Tokuyama, Noriko Yamadori, Masahito Ogura, Akira Kuroe, Yoshikatsu Nakai, Giovanni Vigna, Giancarlo Fabrizio Costantini, Marina Aldini, Alberico Carini, Fabio Catapano, Arianna Schena, Rosanna Tangerini, Egidio Zanca, Paolo Bombardelli, Andrea Morazzoni, Renato Mezzetti, Roberto Fellin, Caroline Perlemoine, Marie-Christine Beauvieux, Vincent Rigalleau, Laurence Baillet, Nicole Barthes, Philippe Derache, Henri Gin, Elsa Brochmann, Maria Duarte, Hasan Zaidi, Samuel Murray, Toshimitsu Yatagai, Tomoatsu Nakamura, Shun Ishibashi, Cheryl Dane-Stewart, Gerald Watts, Sebely Pal, Dick Chan, Peter Thompson, Joseph Hung, John Mamo, Manjunath Rao, Philippe Marmillot, Maokaı ¨gong, David Palmer, Leonard Seeff, Doris Strader, M Lakshman, Scott Lear, Mustafa Toma, C Birmingham, Jiri Frohlich, K Goya, T Kitamura, M Inaba, M Otsuki, H Yamamoto, S Kurebayashi, S Sumitani, H Saito, H Kouhara, S Kasayama, I Kawase
Journal: Metabolism (2003)
Pathology of chronic hepatitis C in children
Authors: M Kage
Journal: Hepatology (1997)

Limited information is available regarding the histology of hepatitis C virus infection in children. The aim of this study was to determine the histological pattern of chronic hepatitis C (CHC) in children, and liver biopsy specimens from 109 pediatric patients with CHC were examined. Each biopsy specimen was evaluated based on a numerical scoring system for the stage of fibrosis (1-4), the grade of portal/periportal necroinflammation (0-4), the grade of lobular necroinflammation (0-4), and their sum (final grade). The histological lesions considered to be characteristic of chronic hepatitis were also evaluated. None of the children had liver cirrhosis, and 105 cases (97%) were stage 1 or 2. Only 4 children were stage 3. Two of these 4 cases showed hemosiderosis. A significant correlation was observed between the staging score and the final grade in the pediatric patients (r = .59; P < .0001). The histological characteristics of adult CHC, such as lymphoid aggregate, bile duct injury, and fatty changes, were also observed in the children. In conclusion, the majority of children with CHC presented with mild fibrosis, but a few showed CHC with lobular distortion and hemosiderosis. Frequent blood transfusion may aggravate hepatic lesions in pediatric CHC.
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Authors: Hervé Maisonneuve
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Colorectal Cancer
Authors: R J Nicholls
Journal: Gut (1981)

<h3>Introduction</h3> Small firms, while more numerous than large firms, often face greater challenges in implementing effective occupational health and safety and return-to-work programs. Research has rarely looked at firm size as a determinant of work disability duration and has been limited to single jurisdictions. <h3>Objectives</h3> To identify whether there were differences in work disability duration between injured workers employed by small, medium and large firms and whether these differences varied between workers’ compensation jurisdictions in Canada (CAN) and Australia (AUS). <h3>Methods</h3> Workers’ compensation data were used to identify comparable lost-time, work-related injury and musculoskeletal disorder claims in five Canadian and five Australian jurisdictions between 2011 and 2015. Work disability duration was measured using cumulative days in receipt of disability benefit payments up to one-year post-injury. Jurisdiction-specific quantile regression models were used to compare cumulative disability days paid from small ( &lt; 2 0 full-time equivalents (FTEs), medium (20–199 FTEs), large (200+ FTEs) firms at 25th, 50th, and 75th percentiles in the disability distribution, adjusting for confounders. <h3>Results</h3> Differences in work disability duration by firm size were observed in all jurisdictions except the Northern Territories (AUS). Compared to large firms, small firms were paid the most disability days at each percentile, particunarly in Victoria (AUS), Saskatchewan (CAN), the Australian Capital Territory, and Tasmania (AUS), where an additional 63.0, 31.1, 37.0, and 27.4 days were paid at the 75th percentiles of the distributions, respectively. Claims from medium-sized firms were generally paid more disability days than large firms except in Western Australia and Tasmania, where they were paid less. <h3>Conclusions</h3> Small firms were shown to have the longest work disability durations in 9 of the 10 study jurisdictions. Claims management processes need to be sensitive to the challenges that small firms face in accommodating and returning injured workers back to work.
The Science of Vital Force;
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal